Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2666 results

Key Release / Apr 02, 2020
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…
Media Release / Mar 28, 2020
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified…
Media Release / Apr 16, 2020
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
Media Release / Apr 02, 2020
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus…
Media Release / Apr 20, 2020
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
Media Release / Apr 20, 2020
Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
Media Release / Apr 21, 2020
Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
Media Release / Apr 22, 2020
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
Media Release / Apr 22, 2020
Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
Key Release / Apr 28, 2020
Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19
Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…